Moderna pops 11% on Jefferies buy rating Shares of drug maker Moderna popped about 11% on Monday after Jefferies initiated coverage of the company with a buy rating. The Wall Street firm said Moderna’s Covid-19 vaccine candidate will be approved and that it could generate about $5 billion in orders over the next few years. “We believe the Street will be surprised to the upside if the COVID-19 vaccine works, gets approved by early 2021, and there are multi-billion dollars of purchase orders from USA and around the world,” a Jefferies analyst told clients. The firm slapped a $90 per share price target on Moderna. Moderna will join the Nasdaq-100 starting July 20.
The fact the offer was open for 3 hours tells you the deals were already done. II do not invest 30 million on a whim. They would of had plenty of time to do due diligence.there has to be good reasons for this investment.hopefully a big name that's new to afc. Good luck to lth. We all deserve it.